Jounce Therapeutics Inc. (NASDAQ: JNCE) Receives IND Approval for JTX-1811 Licensed To Gilead, Shares Drop

June 23, 2021

Jounce Therapeutics Inc. (NASDAQ: JNCE) lost 2.55% after the FDA cleared its anti-CCR8 antibody, JTX-1811, Investigational New Drugs application for Gilead Sciences Inc. (NYSE: GILD) has rights to produce and market. The IND clearance will trigger a milestone payment of $25 million to Jounce.   Jounce developed JTX-1811  JTX-1811 is a monoclonal antibody developed by Jounce and intended to reduce immunosuppressive tumor-infiltrating T regulatory (TITR) cells exclusively. In Gilead’s pipeline, it…